Navigation Links
First Patient Dosed with KX2-391 in Phase 1 Clinical Trial
Date:11/27/2007

BUFFALO, N.Y., Nov. 27 /PRNewswire/ -- Kinex Pharmaceuticals LLC, announced today that their drug KX2-391 (KX01) has begun Phase 1 human testing. The study is entitled "A combined rising single-dose (RSD) and rising multiple-dose (RMD) Phase 1 study to evaluate safety, tolerability and pharmacokinetics of KX2-391 in patients with advanced malignancies that are refractory to conventional therapies". The drug belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

Dosing has begun at Roswell Park Cancer Institute in Buffalo, N.Y., and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas. The trial is expected to enroll 50 patients with advanced solid tumors and lymphoma and will evaluate safety, tolerability and pharmacokinetics. Exploratory biomarker studies will also be involved.

"What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model," said David Hangauer, a University at Buffalo chemistry professor whose work was integral to the drug's creation. Hangauer is a co-founder of Kinex and serves as the Company's Senior Vice President of Research and Development. KX2-391 targets an important cell signaler called Src kinase, a protein linked to the rapid growth and spread of cancer cells. A potential advantage of Kinex's kinase inhibitor is that it disrupts Src at a site different from where other currently studied compounds are targeted, reducing the chance that patients will develop resistance to the new drug, Hangauer said.

"As we go further in the drug's development, and do broader testing, we get better and better data," said Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "We are extremely enthusiastic about the potential for KX2-391 because it represents a unique approach for the treatment of cancer. It is a first-in-class drug that has the potential to provide patients
'/>"/>

SOURCE Kinex Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015 Research and Markets ... of the "Lab Accessories Market by ... Station) & End User (OEM/Biotechnology & Pharmaceutical ... 2020" report to their offering. ... expected to reach $504.7 million by 2020 ...
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/23/2015)... NORTH CHICAGO, Ill. , April 24, 2015 /PRNewswire/ ... U.S. Food and Drug Administration (FDA) has accepted its ... the company,s, all-oral, interferon-free, two direct-acting antiviral treatment of ... is for the treatment of adults with chronic genotype ... AbbVie,s regimen is the first all-oral, interferon-free therapy being ...
Breaking Medicine Technology:Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 2Global Lab Accessories Market Report 2015-2020 - Label Printer/ Pipette tips/ Pumps/Microplate/Reagent Reservoir/Valve/Tubing/Wash Station 3Lannett Expands Revolving Credit Facility To $120 Million 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7
(Date:4/25/2015)... (PRWEB) April 25, 2015 The impact ... still eliciting the excitement of the public and is ... the months of May and June. From March ... their biannual tradition of "Special Prayers." More than 600 ... attended previous Special Prayers and have reported intense experiences ...
(Date:4/25/2015)... 25, 2015 Parker and Sons projects growth ... has spiked in Arizona alongside the growing economy. As a ... employees for April to help account for the rising need ... in April is something we are enthusiastic about. It means ... Kelly, president at Parker and Sons. , Indeed, Parker and ...
(Date:4/25/2015)... 2015 On Friday, April 17, Interstate ... annual Best Implementation Award. This award is given ... use of RFID technology to improve its manufacturing, supply ... that best demonstrates how RFID is delivering real value ... Journal Live! 2015 in San Diego, the RFID industries ...
(Date:4/24/2015)... April 24, 2015 Constellations Recovery celebrates ... in Westchester County. Just 35 miles from New York ... back into everyday life while recovering from addiction. The ... 2015, will allow therapists, doctors and treatment centers to ... more about the opportunities offered by Constellations Recovery.,  , ...
(Date:4/24/2015)... (PRWEB) April 24, 2015 Ryadon is ... wide range of capabilities and services to complement any ... Ryadon's Quantity Discount Program will be offered on all ... , Order 4-19: Receive 10% discount - Order 20+: ... Using the Drawer Slides Products, ...
Breaking Medicine News(10 mins):Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:Parker and Sons Plans to Expand in 2015 2Health News:Seeonic’s Industry Leading Technology Powers Interstate Batteries to Winning Award 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 2Health News:Ryadon Inc. Offers Quantity Drawer Slide Discount Program Nationwide in May 2015 3
... HealthDay Reporter , WEDNESDAY, June 15 (HealthDay News) -- ... leading nations in terms of life expectancy, and the gap ... Life expectancy in some areas of the United States is ... nations, the report found. "The gap between the U.S. ...
... Reporter , WEDNESDAY, June 15 (HealthDay News) -- Severely ... fade or become less frequent after having weight-reducing gastric ... the three years following surgery, 70 percent of the ... saw their migraines reduced from five to two a ...
... as nave and irrational, can actually help consumers cope ... to a new study in the Journal of ... an individual invokes mystical, supernatural forces to understand, predict, ... write authors Yannik St. James (HEC Montreal), Jay M. ...
... 2011, the New York Academy of Sciences will ... molecular biologists and patient advocates to discuss current ... and management of the cognitive symptoms of MS. ... Dysfunction in Multiple Sclerosis: New Approaches to Diagnosis ...
... -- A person scanning baggage or X-rays stands a ... they aren,t feeling anxious, according to a new laboratory ... a test in which they searched for particular shapes ... searching performed by airport security teams and radiologists. ...
... of asbestos-contaminated dust, have a higher level of genetic somatic ... lower. This has been shown in a new study carried ... the University of Haifa,s Department of Biology in Oranim. "This ... higher levels of asbestos in the environment and the frequency ...
Cached Medicine News:Health News:U.S. Found to Be Losing Ground in Life Expectancy 2Health News:U.S. Found to Be Losing Ground in Life Expectancy 3Health News:For Many, Weight-Loss Surgery Also Eases Migraines 2Health News:For Many, Weight-Loss Surgery Also Eases Migraines 3Health News:Magical thinking helps dieters cope with unrealistic expectations 2Health News:The New York Academy of Sciences to host a symposium on cognitive dysfunction in multiple sclerosis 2Health News:Anxious searchers miss multiple objects 2Health News:Genetic mutation linked to asbestos exposure 2
... provide protection to the exposed airway of the ... making it ideal for active young children as ... heat and moisture recovery, it ensures patient comfort ... filters have ISO standard tapered ends to assure ...
... The Portex® Thermovent® T helps provide protection ... It is small and extremely lightweight making it ... adults. With a high rate of heat and ... secretion retention., ,All HMEs and filters have ...
The Leader in ICU Humidification., ,Available Configurations: , Gas Sampling Port, Straight Flex Tube, Poppel Flex Tube, Luer Port for Pressure, Monitoring/Secretion Removal, Special Use Devices, M...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
Medicine Products: